Failed 2023

    Pear Therapeutics

    FDA-approved digital therapeutics don't matter if insurance companies refuse to pay for them.

    TL;DR — Failure Post-Mortem

    Pear Therapeutics was a Healthcare/Digital Therapeutics startup founded in 2013 in USA. It raised $418M before collapsing in 2023 — 10 years of runway burned. IdeaProof's AI Failure Score: 68/100, driven by payer reimbursement failure. The shutdown affected employees, investors, and the broader Healthcare/Digital Therapeutics ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.

    Why did Pear Therapeutics fail?

    Pear Therapeutics failed in 2023 after 10 years of operation, losing $418M in raised capital. The root cause was payer reimbursement failure. Key lesson: FDA-approved digital therapeutics don't matter if insurance companies refuse to pay for them.

    Verifiable facts
    Sourced
    Founded → Closed

    2013 → 2023

    Funding Raised

    $418M

    Industry

    Healthcare/Digital Therapeutics

    Country

    USA

    IdeaProof AI Failure Score

    68/100
    Market Fit Risk
    40
    Burn Rate Risk
    80
    Founder Risk
    25

    What Happened: The Timeline

    🚀

    2013

    Pear Therapeutics founded to create prescription digital treatments

    💰

    2018

    First FDA-cleared prescription app (reSET for substance abuse)

    📈

    2021

    Goes public via SPAC at $1.6B valuation

    ⚠️

    2022

    Revenue only $12.4M, insurers refuse reimbursement

    💀

    Apr 2023

    Files for bankruptcy

    Root Causes

    Insurance Reimbursement
    Doctor Adoption
    New Category Risk
    Revenue Shortfall

    Pear Therapeutics was a pioneer in FDA-approved prescription digital therapeutics (PDTs) — software-based treatments for substance abuse and insomnia. Despite being the first company to receive FDA clearance for prescription apps (reSET, Somryst), Pear couldn't get insurance companies to reimburse for digital treatments. Doctors were unfamiliar with prescribing apps. Revenue reached only $12.4M in 2022 while burning $30M+ per quarter. Pear filed for bankruptcy in April 2023, casting doubt on the entire digital therapeutics industry.

    Causal Chain

    Derived · heuristic

    This is our reading of the causal chain — separated from the verifiable facts above. Timeline dates, funding numbers and filings are facts (see methodology); root / proximate / terminal attribution is judgement based on public evidence.

    Root cause

    A combination of demand-side, execution, and capital-market pressures that this record documents without isolating a single dominant driver.

    Contributing factors
    • Insurance Reimbursement
    • Doctor Adoption
    • New Category Risk
    • Revenue Shortfall
    Proximate cause

    2022: Revenue only $12.4M, insurers refuse reimbursement

    Terminal event

    Apr 2023: Files for bankruptcy

    Base rates

    External sources

    A single failure is an anecdote. These base rates give you the denominator — how common this outcome is across all startups matching Pear Therapeutics's profile. Sources are third-party; we do not restate them as our own claims.

    ~70%
    industry

    of digital-health startups fail to reach breakeven; reimbursement complexity + regulatory approvals extend runway needs beyond typical VC horizons.

    Rock Health State of Digital Health (2023)
    ~90%
    all

    of startups ultimately fail — including ~10% that fail in the first year and the rest across the following decade.

    Startup Genome / CB Insights aggregate (2024)
    ~35%
    all

    of new US employer businesses survive past their 10th year (Bureau of Labor Statistics BED series).

    US Bureau of Labor Statistics — BED (2024)
    ~35%
    stage

    of Series A rounds ever graduate to Series B; the rest run out of runway or pivot without a follow-on.

    CB Insights Venture Capital Funnel (2023)

    Frequently Asked Questions

    Sources & Confidence

    Every data point is tagged with its source type and our confidence in it. How we grade sources.

    Additional references
    STAT News

    Could This Failure Have Been Prevented?

    IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Pear Therapeutics.

    Spotted a factual error?

    Approved corrections are published in the public changelog with attribution.

    After Pear Therapeutics: hubs, comparisons and deep dives

    Compare the validation, funding and go-to-market choices that separate survivors from failures like Pear Therapeutics.